Sweden-based KDventures AB today announced that its portfolio company PharmNovo has completed a capital raise of ...

Amprion and Modality.AI have formed a collaboration to explore the combined use of molecular biomarkers and artificial ...

Roche (ROG: SIX) has discontinued two Huntington’s disease programs, ending the long-running development of tominersen after ...

GSK (LSE: GSK) has terminated its neurodegeneration collaboration with Alector (Nasdaq: ALEC), ending an alliance established ...

A clinical-stage biopharmaceutical company pioneering immunometabolism-based therapies to treat chronic autoimmune and inflammatory diseases through oral small molecules that modulate immune cell ...

Israeli drugmaker Teva Pharmaceutical Industries has expanded its biosimilars pipeline through a global licensing agreement ...

India's Dr Reddy's Laboratories today revealed that supplies of its generic semaglutide would remain unavailable in India and ...

Anglo-Swedish pharma major AstraZeneca has licensed ex-China rights to TQC3721, an investigational inhaled PDE3/4 inhibitor ...

The US Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for Zoryve (roflumilast) ...

A Massachusetts-based biotechnology company formerly known as Vaxess Technologies, Terrestrial Bio is developing a proprietary microarray patch platform that enables the temperature-stable, ...

The CARDIO-TTRansform Phase III trial for AstraZeneca (LSE: AZN) and Ionis Pharmaceuticals (Nasdaq: IONS), Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) ...

UK biotech company Alchemab Therapeutics has secured a £25 million ($34 million) Series A extension from the British Business Bank, in what the bank says is its largest direct investment in a life ...